Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bevacizumab + Dexamethasone + Evofosfamide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 10 VEGFR Inhibitor (Pan) 32||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Evofosfamide||TH-302||Chemotherapy - Alkylating 14||Evofosfamide (TH-302) is a hypoxia-activated prodrug that releases a DNA-alkylating dibromo isophosphoramide mustard moiety within hypoxic regions of tumors, potentially providing antineoplastic activity with reduced systemic toxicity (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||Bevacizumab + Dexamethasone + Evofosfamide||Phase Ib/II||Actionable||In a Phase I/II trial, treatment with combined Avastin (bevacizumab), Evofosfamide (TH-302) therapy, and Adexone (dexamethasone) was well tolerated in patients with relapsed/refractory multiple myeloma and resulted in a disease control rate of 78.6% (22/28, stable disease or better), 3.6% (1/28) complete and 7.1% (2/28) partial responses, a 25% 6-month progression-free survival rate, a median progression-free survival of 2.2 months, and a median overall survival of 9.0 months (PMID: 30279233; NCT01522872).||30279233|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|